A Phase 1 interventional study of LY2963016 and Lantus in Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 1 site in South Africa. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by Eli Lilly and Company · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 41st largest by enrollment, is one of 11 that started in 2011, is one of 13 in phase 1, and was the 58th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–50 · Women only
Medical University of Warsaw · Sites in Poland
Ages 18+
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 80 across the 81 interventional studies. Of the 75 that completed or were terminated, 31 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 81 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
48 studies in Diabetes Mellitus by Eli Lilly and Company: none open now, 4 under way, 1 of them phase 3. Of 43 finished, 35 (81%) have results posted.
Among the 48 studies in Diabetes Mellitus by Eli Lilly and Company, this one is the 38th largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2011, is one of 5 in phase 1, and was the 29th registered.
Eli Lilly and Company’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 48 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy participants.
Each study period will be approximately 8.5 days (1.5 days for treatment and 7 day washout period). There are 4 study periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
are overtly healthy males or females, as determined by medical history and physical examination
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
Drug: LY2963016
A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
Drug: Lantus
Administered subcutaneously
Administered subcutaneously
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus
Time frame: 1 hour predose up to 24 hours postdose in all treatment periods
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus
Time frame: 1 hour predose up to 24 hours postdose in all treatment periods
Maximum Glucose Infusion Rate (Rmax)
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
Time frame: 1 hour predose up to 24 hours postdose in all treatment periods
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
Time frame: 1 hour predose up to 24 hours postdose in all treatment periods
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 40 | 40 |
| Received at least 1 dose of study drug | 40 | 40 |
| Completed | 40 | 40 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 40 | 40 |
| Completed | 40 | 40 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 39 |
| Not completed | 0 | 0 |
| Milestone | LY/Lantus/LY/Lantus | Lantus/LY/Lantus/LY |
|---|---|---|
| Started | 39 | 39 |
| Completed | 39 | 39 |
| Not completed | 0 | 0 |
| picomoles*hour/Liter (pmol*h/L) | LY2963016 | Lantus |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus | 1810 ± 40 | 1980 ± 36 |
| picomoles/Liter (pmol/L) | LY2963016 | Lantus |
|---|---|---|
| Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus | 112 ± 39 | 119 ± 34 |
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
| milligrams/kilogram/minute (mg/kg/min) | LY2963016 | Lantus |
|---|---|---|
| Maximum Glucose Infusion Rate (Rmax) | 2.85 ± 46 | 2.88 ± 41 |
Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.
| milligrams/kilogram (mg/kg) | LY2963016 | Lantus |
|---|---|---|
| Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure | 2580 ± 45 | 2710 ± 40 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 | — | 0/80 (0%) | 50/80 (62.5%) |
| Lantus | — | 0/80 (0%) | 54/80 (67.5%) |
| Event | LY2963016 | Lantus |
|---|---|---|
| HeadacheNervous system disorders | 15/80 | 25/80 |
| Procedural site reactionInjury, poisoning and procedural complications | 17/80 | 17/80 |
| Injection site painGeneral disorders | 5/80 | 6/80 |
| NauseaGastrointestinal disorders | 4/80 | 5/80 |
| DiarrhoeaGastrointestinal disorders | 4/80 | 1/80 |
| Injection site erythemaGeneral disorders | 4/80 | 2/80 |
| DysmenorrhoeaReproductive system and breast disorders | 1/24 | 0/24 |
All randomized participants.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 32.0 ± 10.9 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 24 |
| Male | 56 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 64 |
| More than one race | 6 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| South Africa | 80 |
The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine